

**Kirkpatrick & Lockhart Nicholson Graham LLP**

State Street Financial Center  
One Lincoln Street  
Boston, MA 02111-2950  
617.261.3100  
Fax: 617.261.3175

**FAX**

---

**Date •** August 29, 2006**Pages •** 20 (including this page)**Time •****Transmit To •** Certificate of Corrections Branch**Company/Firm •** United States Patent and Trademark Office**Telephone No. •****Fax No. •** 703-308-6672**From •** Ronda P. Moore, D.V.M.**Phone •** 617.261.3167**Secretary •** Brenda L. MacLean**Phone •** 617.261.3279**Attorney No. •** 5989**Client/Matter Name**

---

**Client ID/Matter No. •** 0518960/0104

---

**COMMENTS:** Attached is a copy of a Request for Certificate of Correction for U.S. Patent No. 6,855,509, that was originally received by the USPTO on April 7, 2005. A copy of the date stamped postcard is attached. The Office claims to not have received this Request and has asked that we resend the original submission via facsimile so that the Request can be processed.

---

When you are sending to us, please be sure to include a cover sheet with your transmittal and a telephone number where you can be contacted in case of equipment malfunction.

**Transmitted by:****Time:**

---

**IMPORTANT:** The materials transmitted by this facsimile are sent by an attorney or his/her agent, and are considered confidential and are intended only for the use of the individual or entity named. If the addressee is a client, these materials may also be subject to applicable privileges. If the recipient of these materials is not the addressee, or the employee or agent responsible for the delivery of these materials to the addressee, please be aware that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us at 617.951.9140 (collect) and return the transmitted materials to us at the above address via the U.S. Postal Service. We will reimburse you any costs incurred in connection with this erroneous transmission and your return of these materials. Thank you. Please report problems with reception by calling 617.951.9140.

BOS-1001532 v1

INL-053  
(0518960.0104)

The "RECEIVED" stamp of the U.S. Patent and Trademark Office imprinted hereon acknowledges the filing of:

Transmittal Form (1 page); Request for Certificate of Correction (2 pages); Form PTO-1050 (1 page); Exhibit A - Amendment After Allowance Pursuant to 37 U.S.C. §1.312, mailed September 30, 2004 (8 pages); Exhibit B - Response to Rule 312 Communication, mailed December 9, 2004 (2 pages); Power of Attorney by Assignee of Entire Interest/Revocation of Prior Powers and New Power of Attorney (1 page); and this return receipt postcard, all mailed under a Certificate of First Class Mailing.


Applicant(s): Dai *et al.*

Patent No.: 6,855,509

Atty: RPMoore/CAKomm

Date: April 5, 2005

BOS 819123




PATENT  
Attorney Docket No. INL-053

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Dai *et al.* CONFIRMATION NO.: 3767  
SERIAL NO.: 10/029,406 GROUP NO.: 1651  
FILING DATE: December 19, 2001 EXAMINER: S. Saucier  
PATENT NO.: 6,855,509 ISSUE DATE: February 15, 2005  
TITLE: Protein S Functional Assay and Kit Therefor

**CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8**

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 5th day of April, 2005.

  
Brenda L. MacLean

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith are:

1. Transmittal Form (1 page);
2. Request for Certificate of Correction (2 pages);
3. Form PTO-1050 (1 page);
4. Exhibit A – Amendment After Allowance Pursuant to 37 U.S.C. §1.312, mailed September 30, 2004 (8 pages);
5. Exhibit B – Response to Rule 312 Communication, mailed December 9, 2004 (2 pages); and
6. Power of Attorney by Assignee of Entire Interest/Revocation of Prior Powers and New Power of Attorney (1 page).

# TRANSMITTAL FORM

Application Serial Number	10/029,406
Filing Date	December 19, 2001
First Named Inventor	Dai
Group Art Unit	1651
Examiner Name	S. Saucier
Patent No.	6,855,509
Attorney Docket No.	INL-053
Confirmation No.	3767


## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form  <input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson  including Drawings [Total Sheets ____]  <input type="checkbox"/> Petition for Extension of Time  <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Form PTO-1449 <input type="checkbox"/> Copies of IDS Citations  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Sequence Listing submission  <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application  <input type="checkbox"/> Formal Drawing(s)  <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal  <input checked="" type="checkbox"/> Power of Attorney by Assignee of Entire Interest/Revocation of Prior Powers and New Power of Attorney (1 page)  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Application  <input type="checkbox"/> Small Entity Statement  <input type="checkbox"/> CD(s) for large table or computer program  <input type="checkbox"/> Amendment After Allowance  <input checked="" type="checkbox"/> Request for Certificate of Correction (2 pages) <input checked="" type="checkbox"/> Certificate of Correction (1 page)	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences  <input type="checkbox"/> Appeal Brief (in triplicate)  <input type="checkbox"/> Status Inquiry  <input checked="" type="checkbox"/> Return Receipt Postcard  <input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 (1 page)  <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 Additional Enclosure(s) (please identify below)  Exhibit A – Amendment After Allowance Pursuant to 37 U.S.C. § 1.312, mailed September 30, 2004 (8 pages)  Exhibit B – Response to Rule 312 Communication, mailed December 9, 2004 (2 pages).
---	---	---

## CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator  
 Kirkpatrick & Lockhart Nicholson  
 Graham LLP  
 75 State Street  
 Boston, MA 02109-1808  
 Tel. No.: (617) 261-3100  
 Fax No.: (617) 261-3175

## SIGNATURE BLOCK

Respectfully submitted,  
  
 Ronda P. Moore, D.V.M.  
 Attorney for Applicants  
 Kirkpatrick & Lockhart Nicholson  
 Graham LLP  
 75 State Street  
 Boston, MA 02109-1808

Date: April 5, 2005  
 Reg. No. 44,244  
 Tel. No.: (617) 261-3167  
 Fax No.: (617) 261-3175

PATENT  
Attorney Docket No. INL-053

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

INVENTORS: Dai *et al.* ASSIGNEE: Instrumentation Laboratory Company  
PATENT NO.: 6,855,509 ISSUE DATE: February 15, 2005  
TITLE: Protein S Functional Assay and Kit Therefor

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST**  
**REVOCATION OF PRIOR POWERS AND NEW POWER OF ATTORNEY**

Sir:

As an authorized representative of the assignee of record of the entire right, title, and interest in the above-identified patent, I hereby revoke all powers of attorney previously given and hereby appoint the registered patent practitioners associated with **Customer Number 022832** to prosecute and transact all business in the U.S. Patent and Trademark Office connected therewith.

Please direct all correspondence for the above-identified patent to the address associated with the above Customer Number.

The assignee of record of the entire right, title, and interest in the above-identified patent is Instrumentation Laboratory Company by virtue of the chain of title from the inventors of the above-identified patent to the current assignee, as shown below:

By assignment from inventors Yong Dai, Biqing Ye, Kui Chen, Pau Bruguera, Daniel E. Lawson, and ShaMay Tang to Instrumentation Laboratory Company, recorded in the U.S. Patent and Trademark Office on September 23, 2002, at Reel No. 013314, Frame No. 0876.

Respectfully submitted,



Dated: MAR 30, 2005

James A. Clayton, Jr., Esq.  
Vice President, Legal and Human Resources  
Instrumentation Laboratory Company  
101 Hartwell Ave.  
Lexington, MA 02421

PATENT  
Attorney Docket No. INL-053

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

INVENTORS: Dai *et al.*  
PATENT NO.: 6,855,509  
ISSUE DATE: February 15, 2005  
SERIAL NO.: 10/029,406  
FILING DATE.: December 19, 2001  
TITLE: Protein S Functional Assay and Kit Therefor

ATTN: Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR CERTIFICATE OF CORRECTION**

Dear Sir:

The Assignee of record of the above-identified patent, Instrumentation Laboratory Company, by virtue, at least, of an assignment recorded in the U.S. Patent and Trademark Office on September 23, 2002, at Reel No. 013314, Frame No. 0876, hereby requests that a Certificate of Correction be issued for U.S. Patent No. 6,855,509 under 35 U.S.C. § 254 and 37 C.F.R. § 1.322.

Specifically, the Assignee requests the correction of an error in the listing of the claims to correct the omission of claim 27 from the published patent. Claim 27 was newly introduced as new claim 78 in an Amendment After Allowance pursuant to 37 U.S.C. § 1.312, filed on September 30, 2004. A copy of the September 30, 2004 Amendment as filed, the transmittal form, a date-stamped return receipt postcard and Express Mail Mailing Label are attached as Exhibit A (claim 78 is highlighted). The Examiner entered the Amendment After Allowance as indicated in the Response to Communication under Rule 312, mailed from the United States Patent and Trademark Office on December 9, 2004, which is attached as Exhibit B. In view of the above, the Assignee respectfully submits that the error in U.S. Patent No. 6,855,509 is due to a Patent Office mistake and is therefore correctable pursuant to 35 U.S.C. § 1.322.

A copy of a computer generated Form PTO-1050 is enclosed. The Assignee believes that the enclosed Form PTO-1050 corrects the error in the claims of column 16. The following is a summary of the content of the enclosed Form PTO-1050:

Request for Certificate of Correction  
U.S. Patent No. 6,855,509  
Page 2 of 2

At column 16, line 24, directly after claim 26, the following claim should be inserted:

--27. The kit of claim 16 wherein the activated protein C comprises recombinant protein C.--


The Assignee believes that the error described above warrants issuance of a certificate of Correction for U.S. Patent No. 6,855,509. Accordingly, the Assignee encloses the aforementioned Form PTO-1050 to correct the error in the above-identified patent and requests that the Commissioner issue a Certificate of Correction reflecting the change to U.S. Patent No. 6,855,509 as it appears on the enclosed Form PTO-1050.

The Assignee believes no fee is necessitated by this Request for a Certificate of Correction as the error apparently arose due to a Patent Office mistake. If a fee is nevertheless due, please charge Attorney's Deposit Account No. 50-1721. The Patent Office is invited to call the undersigned attorney with any questions concerning submission of this paper.

Respectfully submitted,

Date: April 5, 2005  
Reg. No. 44,244

Tel. No.: (617) 261-3167  
Fax No.: (617) 261-3175

  
Ronda P. Moore, D.V.M.  
Attorney for the Applicants  
Kirkpatrick & Lockhart Nicholson  
Graham LLP  
75 State Street  
Boston, Massachusetts 02109-1808

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,855,509  
DATED : February 15, 2005  
INVENTOR(S) : Dai et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 16, line 24, directly after claim 26, the following claim should be inserted:

--27. The kit of claim 16 wherein the activated protein C comprises recombinant protein C.--

MAILING ADDRESS OF SENDER: Patent Administrator  
Kirkpatrick & Lockhart  
Nicholson Graham LLP  
75 State Street  
Boston, MA 02109-1808  
(617) 261-3100

PATENT NO.: 6,855,509



# Exhibit A

(8 pages)

Express Mail Label No. EV334240723US

PATENT  
Atty. Docket No. INL-053  
(4643/95)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Dai *et al.* CONFIRMATION NO.: 3767  
SERIAL NUMBER: 10/029,406 ART UNIT: 1651  
FILING DATE: December 19, 2001 EXAMINER: S. Saucier  
TITLE: Protein S Functional Assay and Kit Therefor

**AMENDMENT AFTER ALLOWANCE****PURSUANT TO 37 C.F.R. § 1.312****EXPEDITED HANDLING**

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the "Notice of Allowance and Fee(s) Due" (PTOL-85), including an Examiner's Amendment, mailed September 15, 2004, please amend the above-identified patent application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks** begin on page 5 of this paper.

Application Serial No.: 10/029,406

Amendment After Allowance dated September 30, 2004

Page 2 of 5

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application once entered by the Examiner:

1-51. (Canceled).

52. (Currently Amended) A method for measuring protein S activity in a test plasma sample comprising:

(a) mixing a sample of test plasma with protein S deficient plasma,  
at least one recombinant tissue factor selected from the group consisting of recombinant rabbit, recombinant porcine, recombinant equine and recombinant human tissue factors,  
purified or synthetic phospholipids comprising phosphocholine, phosphoserine and phosphoethanolamine[.],  
activated protein C,  
calcium ion,

and measuring a clotting time of the sample,

(b) comparing the measurement in (a) to a standard curve derived from clotting times of plasma samples having a range of known protein S activities.

53. (Previously Presented) The method of claim 52 wherein the phospholipids comprise 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine.

54. (Previously Presented) The method of claim 53 wherein the molar ratio of 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine is about 3 to about 4 to about 5.

55. (Previously Presented) The method of claim 52 wherein the activated protein C has been activated by thrombin.

56. (Previously Presented) The method of claim 52 wherein the activated protein C has been activated by snake venom.

Application Serial No.: 10/029,400

Amendment After Allowance dated September 30, 2004

Page 3 of 5

57. (Previously Presented) The method of claim 52 wherein the activated protein C comprises recombinant protein C.
58. (Previously Presented) The method of claim 52 wherein one or more of the protein S deficient plasma, recombinant tissue factor and activated protein C is derived from a mammalian source selected from the group consisting of a cow, a pig and a rabbit.
59. (Previously Presented) The method of claim 52 wherein one or more of the protein S deficient plasma, recombinant tissue factor and activated protein C is derived from a human.
60. (Previously Presented) The method of claim 52 wherein the measuring step is chromogenic.
61. (Currently Amended) The method of claim 52 wherein the measuring step is ~~spectrophotometric~~spectrophotometric.
62. (Previously Presented) The method of claim 52 wherein the at least one recombinant tissue factor comprises a recombinant rabbit tissue factor.
63. (Previously Presented) The method of claim 52 wherein the at least one recombinant tissue factor comprises a recombinant porcine tissue factor.
64. (Previously Presented) The method of claim 52 wherein the at least one recombinant tissue factor comprises a recombinant equine tissue factor.
65. (Previously Presented) The method of claim 52 wherein the at least one recombinant tissue factor comprises a recombinant human tissue factor.
66. (Previously Presented) The method of claim 52 wherein the at least one recombinant tissue factor is purified from mammalian cells.
67. (Previously Presented) A kit for measuring the functional activity of protein S in a plasma sample, said kit comprising one or more containers containing  
protein S deficient plasma,  
at least one recombinant tissue factor selected from the group consisting of recombinant rabbit, recombinant porcine, recombinant equine and recombinant human tissue factors,

Application Serial No.: 10/029,400

Amendment After Allowance dated September 30, 2004

Page 4 of 5

purified or synthetic phospholipids comprising phosphocholine, phosphoserine and phosphoethanolamine,

calcium ion and

activated protein C.

68. (Previously Presented) The kit of claim 67 further comprising calibration plasma comprising about 100% percent protein S activity for preparing a standard curve.

69. (Previously Presented) The kit of claim 67 further comprising normal control plasma comprising between about 40-50% protein S activity.

70. (Previously Presented) The kit of claim 67 wherein the phospholipids comprise 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine.

71. (Currently Amended) The kit of claim ~~[[67]]~~70 wherein the molar ratio of 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine is about 3 to about 4 to about 5.

72. (Previously Presented) The kit of claim 67 wherein the at least one recombinant tissue factor comprises a recombinant rabbit tissue factor.

73. (Previously Presented) The kit of claim 67 wherein the at least one recombinant tissue factor comprises a recombinant porcine tissue factor.

74. (Previously Presented) The kit of claim 67 wherein the at least one recombinant tissue factor comprises a recombinant equine tissue factor.

75. (Previously Presented) The kit of claim 67 wherein the at least one recombinant tissue factor comprises a recombinant human tissue factor.

76. (Previously Presented) The kit of claim 67 wherein the at least one recombinant tissue factor is purified from mammalian cells.

77. (Previously Presented) The kit of claim 67 further comprising a chromogenic substrate.

78. (New) The kit of claim 67 wherein the activated protein C comprises recombinant protein C.

Application Serial No.: 10/029,~000

Amendment After Allowance dated September 30, 2004

Page 5 of 5

### REMARKS

Claims 52-77 have been allowed as indicated in the Notice of Allowance mailed September 15, 2004. Applicants have not submitted or otherwise authorized payment of the issue fee. Through this paper, Applicants have amended claims 52 and 61 to correct typographical errors. Claim 71 has been amended to recite the appropriate dependency. New dependent claim 78 has been added. Support for these amendments and the new claim can be found throughout the application including the claims as originally filed. Applicants believe these amendments introduce no new matter.

The undersigned attorney has received the Examiner's amendment with appreciation and respectfully requests that the amendments contained herein be entered.

Applicants also respectfully request that the Examiner return to the undersigned an initialed copy of Form PTO-1449 submitted January 29, 2004, as it has not yet been received. For the Examiner's convenience, a copy of the submission of January 29, 2004, along with a copy of the date-stamped mailroom postcard indicating the submission was received by the Patent Office on February 2, 2004, are attached as Exhibit A.

If any additional fees are required by this submission, the Commissioner is hereby authorized to charge Attorney's Deposit Account No. 20-0531.

Respectfully submitted,



Date: September 30, 2004  
Reg. No. (Limited Recognition  
Under CFR 10.9(b))  
Tel. No. (617) 248-7808  
Fax No. (617) 248-7100

Duan Wu  
Attorney for Applicants  
Testa, Hurwitz, & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110

Express Mail Mailing Label No. EV334240723US

TRANSMITTAL  
FORM

Application Serial Number	10/029,406
Filing Date	December 19, 2001
First Named Inventor	Dai
Group Art Unit	1651
Examiner Name	Saucier, Sandra
Attorney Docket No.	INL-053
Confirmation No.	3767


## ENCLOSURES (check all that apply)

- |   |   |   |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Check Attached<br><input type="checkbox"/> Copy of Fee Transmittal Form<br><br><input type="checkbox"/> Amendment/Response<br><input type="checkbox"/> Preliminary<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____]<br><br><input type="checkbox"/> Petition for Extension of Time<br><br><input type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Form PTO-1449<br><input type="checkbox"/> Copies of IDS Citations<br><br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><br><input type="checkbox"/> Sequence Listing submission<br><input type="checkbox"/> Paper Copy/CD<br><input type="checkbox"/> Computer Readable Copy<br><input type="checkbox"/> Statement verifying identity of above | <input type="checkbox"/> Copy of Notice to File Missing Parts of Application<br><br><input type="checkbox"/> Formal Drawing(s)<br><br><input type="checkbox"/> Request For Continued Examination (RCE) Transmittal<br><br><input type="checkbox"/> Power of Attorney (Revocation of Prior Powers)<br><br><input type="checkbox"/> Terminal Disclaimer<br><br><input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application<br><br><input type="checkbox"/> Small Entity Statement<br><br><input type="checkbox"/> CD(s) for large table or computer program<br><br><input type="checkbox"/> Amendment After Allowance<br><br><input type="checkbox"/> Request for Certificate of Correction<br><input type="checkbox"/> Certificate of Correction (in duplicate) | <input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences<br><br><input type="checkbox"/> Appeal Brief (in triplicate)<br><br><input type="checkbox"/> Status Inquiry<br><br><input checked="" type="checkbox"/> Return Receipt Postcard<br><br><input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8<br><br><input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8<br><br><input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below)<br><br><input checked="" type="checkbox"/> Amendment After Allowance Pursuant to 37 C.F.R. §1.312 (5 pgs.)<br><input checked="" type="checkbox"/> "Exhibit A" Copy of Submission of an Information Disclosure Statement of January 29, 2004 (17 pgs.) |
|---|---|---|




## CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator  
 Testa, Hurwitz & Thibault, LLP  
 High Street Tower  
 125 High Street  
 Boston, MA 02110  
 Tel. No.: (617) 248-7000  
 Fax No.: (617) 248-7100

## SIGNATURE BLOCK

Respectfully submitted,  
  
 Date: September 30, 2004  
 Reg. No. Limited Recognition  
 Tel. No.: (617) 248-7808  
 Fax No.: (617) 248-7100  
 Duan Wu  
 Attorney for the Applicants  
 Testa, Hurwitz & Thibault, LLP  
 High Street Tower  
 125 High Street  
 Boston, MA 02110

BEST AVAILABLE COPY

 EV 334240723 US		<b>Customer Co</b> Label 11-F June	
		<b>EXPRESS MAIL</b> UNITED STATES POSTAL SERVICE®	
<b>Post Office To Address</b>			
<b>ORIGIN (POSTAL USE ONLY)</b>		<b>DELIVERY (POSTAL USE ONLY)</b>	
<b>PO ZIP Code</b> 02225	<b>Day of Delivery</b> <input checked="" type="checkbox"/> Next <input type="checkbox"/> Second	<b>Flat Rate Envelope</b> <input type="checkbox"/>	<b>Delivery Attempt</b> Time <input type="checkbox"/> AM <input type="checkbox"/> PM
<b>Date In</b> Mo. 9 Day 13 Year 04	<input checked="" type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	<b>Postage</b> \$ 13.15	<b>Delivery Attempt</b> Time <input type="checkbox"/> AM <input type="checkbox"/> PM
<b>Time In</b> <input type="checkbox"/> AM <input checked="" type="checkbox"/> PM	<b>Military</b> <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	<b>Return Receipt Fee</b> 	<b>Delivery Date</b> Time <input type="checkbox"/> AM <input type="checkbox"/> PM
<b>Weight</b> lbs. 5.8 ozs.	<b>Int'l Alpha Country Code</b> 	<b>COD Fee</b> 	<b>Insurance Fee</b> 
<b>No Delivery</b> <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	<b>Acceptance Clerk Initials</b> VH	<b>Total Postage &amp; Fees</b> \$ 13.15	
<b>CUSTOMER USE ONLY</b>		<b>DELIVERY (POSTAL USE ONLY)</b>	
<b>METHOD OF PAYMENT</b> Express Mail Corporate Acct. No. 4022220		<b>Federal Agency/ Acct. No. or Postal Service Acct. No.</b> 	
<b>FROM: (PLEASE PRINT)</b> <b>PHONE:</b>		<b>TO: (PLEASE PRINT)</b> <b>PHONE:</b>	
<b>POSTA HUMWITZ &amp; THIBEAULT LLP</b> 125 HIGH ST FL 20 BOSTON MA 02110-2704 NL-053 (4543/95) CAX 1723 10/029,406		<b>Mail Stop Issue Fee</b> <b>Commissioner for Patents</b> P.O. Box 1450 Alexandria, VA 22313-1450	
<b>PRESS HARD.</b> You are making 3 copies. <b>FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com</b> 			



INL-05  
(4643/95)

The "RECEIVED" stamp of the United States Patent and Trademark Office  
imprinted hereon acknowledges the filing of:



Transmittal Form (1 pg.); Amendment After Allowance Pursuant to 37 C.F.R. § 1.312  
(5 pgs.); Exhibit A: Copy of Submission of Information Disclosure Statement and Related  
Papers on January 29, 2004 (17 pgs.); and this return receipt postcard, with each paper  
bearing Express Mail Mailing Label No. EV334240723US to Mail Stop Issue Fee.

Name of Applicant: Dai *et al.*

Serial Number: 10/029,406

Atty: DWw/CAKomm

Date: September 30, 2004  
3123737

**RECEIVED**

Patent Administrator

Intellectual Property Department

Testa, Hurwitz & Thibault L.L.P.

125 High Street

Boston, MA 02110-2702

TESTA, HURWITZ & THIBEAULT, LLP  
PATENT DEPARTMENT



# Exhibit B

(2 pages)



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/029,406	12/19/2001	Yang Dai	INL-053 (4643/95)	3767
21323	7590	12/09/2004		
TESTA, HURWITZ & THIBEAULT, LLP HIGH STREET TOWER 125 HIGH STREET BOSTON, MA 02110				
			EXAMINER SAUCIER, SANDRA E	
			ART UNIT 1651	PAPER NUMBER

DATE MAILED: 12/09/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

DEC 13 2004

TESTA, HURWITZ & THIBEAULT, LLP

No Docketing Necessary

KFS 12-1304  
Administrator Date  
Signed PTO 1449 Recvd?  
Reviewed & Approved

DW 12-13  
Resp. Atty Date

<b>Response to Rule 312 Communication</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/029,406	DAI ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Sandra Saucier	1651	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☒ The amendment filed on 30 September 2004 under 37 CFR 1.312 has been considered, and has been:

a) ☒ entered.

b) ☐ entered as directed to matters of form not affecting the scope of the invention.

c) ☐ disapproved because the amendment was filed after the payment of the issue fee.

Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

d) ☐ disapproved. See explanation below.

e) ☐ entered in part. See explanation below.

ATTACHED is PTO-1449 9/30/04 - Signed



Sandra Saucier  
Primary Examiner  
Art Unit: 1651